Oncology

In an interview with dvm360®, Sue Ettinger, DVM, DACVIM (Oncology)—known as Dr Sue Cancer Vet—discusses reasons why some pet owners decline to have their dogs provided with treatment for lymphoma and how veterinarians can help clients address these challenges.

Anivive Lifesciences Inc Founder, CEO and Chairman Dylan Balsz discussed the company’s mission and how it is working to serve unmet needs in veterinary health.

In an interview with dvm360®, Sue Ettinger, DVM, DACVIM (Oncology)—Dr Sue Cancer Vet—offers insight about what to tell pet owners when their dog has been diagnosed with lymphoma.

Anivive Lifesciences' Chief Commerical Officer Chad Todd, DVM, offers insight on Laverdia-CA1, the first conditionally approved oral treatment for canine lymphoma.

Virbac’s tigilanol tiglate injections (Stelfonta) has been approved by the FDA for treatment of the most common type of skin cancer in dogs.

During a session at an AVMA Virtual Convention, a veterinary cancer specialist discusses key facts about the disease to help clients make the best decision for their pet.

OncoK9 offers new cancer-detection capabilities enabling veterinarians to provide the highest quality of care to their canine patients.

A survey from the Pet CancerCare Alliance provides insight into pet owners' attitudes about cancer and how likely they are to pursue treatment. (Sponsored by VCA)

From the clinical examination to procedure and treatment methods to the outcome, discover this beagle’s experience undergoing radiation therapy for an MCT.

The association’s Oncology Working Group aims to establish clear guidelines with the goal of enhancing the quality of care provided to patients and education offered to pet owners.

Expand your practical knowledge with these articles highlighting the latest in veterinary cancer diagnosis and treatment.

Considerations for the use of echocardiography to evaluate suspected tumors located in the heart.

Check out this week's news.

A sneak peek at this week’s headlines.

Laverdia-CA1 provides an additional treatment option for dogs suffering from this devastating illness.

A renowned veterinary oncologist outlines the current knowledge about this cancer of the blood vessel walls, from presentation to prognosis.

Cancer diagnostics and therapeutics continue to evolve, potentially lessening the associated invasiveness, duration, and cost.

These 1-hour events will address a wide array of veterinary topics including owner compliance, pet insurance, oncology, and telemedicine.

The simple blood test employs technology that looks for very early nucleosomic markers of cancer in dogs.

A little sneak peek at this week’ headlines.

When veterinarians and veterinary teams work as a cohesive team, workflow is smoother and patient and client care improves.

Early detection of disease is key to maximizing an older dog’s quality of life. Teaching owners about common ailments can help these ptients get appropriate treatment sooner rather than later.

You’ve just made a cancer diagnosis and offered an oncology referral to the owner, but they won’t go. Now what?

An uncommon but life-saving surgery gave a Labrador retriever and his grateful owner much more time together.

Genomic based-precision medicine from the TGen subsidiary provides additional resources to assist both veterinary oncologists and pet owners in the diagnostics and treatment of canine cancer.

Under new ownership and leadership, the company reasserts its mission of providing affordable, innovative therapies for canine joint disease and cancer.

Top headlines of the week: State VMAs endorse Feline Fix by Five Months, rabies update, drug DISCO, and The Vet Blast Podcast with guest Steve Dale.

A look at the One Health initiative that is stepping beyond science to generate more treatments more quickly for canine and human cancer.

Immunotherapy — using an individual’s own immune system to fight disease — is one of the fastest-growing areas in both human and veterinary research. Here’s the latest.

Apocrine gland anal sac adenocarcinoma is an aggressive cancer that might be better harnessed with targeted chemotherapeutic agents. A recent study evaluated the efficacy of toceranib in treating this tumor, and assessed prognostic factors.